JP2022505663A5 - - Google Patents
Info
- Publication number
- JP2022505663A5 JP2022505663A5 JP2021522078A JP2021522078A JP2022505663A5 JP 2022505663 A5 JP2022505663 A5 JP 2022505663A5 JP 2021522078 A JP2021522078 A JP 2021522078A JP 2021522078 A JP2021522078 A JP 2021522078A JP 2022505663 A5 JP2022505663 A5 JP 2022505663A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- fragment
- domain
- receptor
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749429P | 2018-10-23 | 2018-10-23 | |
| US62/749,429 | 2018-10-23 | ||
| PCT/US2019/057702 WO2020086745A1 (en) | 2018-10-23 | 2019-10-23 | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505663A JP2022505663A (ja) | 2022-01-14 |
| JP2022505663A5 true JP2022505663A5 (enExample) | 2022-10-28 |
Family
ID=70331240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522078A Pending JP2022505663A (ja) | 2018-10-23 | 2019-10-23 | ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210380701A1 (enExample) |
| EP (1) | EP3870223A4 (enExample) |
| JP (1) | JP2022505663A (enExample) |
| KR (1) | KR20210083260A (enExample) |
| CN (1) | CN112839677A (enExample) |
| AU (1) | AU2019368289A1 (enExample) |
| CA (1) | CA3113268A1 (enExample) |
| IL (1) | IL281901A (enExample) |
| MX (1) | MX2021004660A (enExample) |
| SG (1) | SG11202103720XA (enExample) |
| WO (1) | WO2020086745A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| MX2019011986A (es) | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| MX2020009069A (es) * | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| JP2022544405A (ja) | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| EP4139362A2 (en) * | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| CN116813759B (zh) * | 2022-03-21 | 2025-11-28 | 中国科学院微生物研究所 | 纳米抗体r14的构建体及其应用 |
| US20250326844A1 (en) * | 2022-04-07 | 2025-10-23 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
| AU2023253516A1 (en) * | 2022-04-15 | 2024-11-21 | Imbiologics Corp. | Fusion protein platform with improved half-life |
| WO2024073700A2 (en) * | 2022-09-30 | 2024-04-04 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2257861A1 (en) * | 1996-06-14 | 1997-12-18 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| ES2538122T3 (es) * | 2008-07-21 | 2015-06-17 | Apogenix Gmbh | Moléculas de una sola cadena de TNFSF |
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| EP3105250B1 (en) * | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| IL308212A (en) * | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) * | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) * | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP2019530640A (ja) * | 2016-07-20 | 2019-10-24 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体ｏｘ４０結合分子及びその使用 |
| MX2019000799A (es) * | 2016-07-20 | 2019-06-03 | Igm Biosciences Inc | Moleculas de union a gitr multimericas y usos de las mismas. |
| MX2019011986A (es) * | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
-
2019
- 2019-10-23 US US17/287,828 patent/US20210380701A1/en not_active Abandoned
- 2019-10-23 WO PCT/US2019/057702 patent/WO2020086745A1/en not_active Ceased
- 2019-10-23 CA CA3113268A patent/CA3113268A1/en active Pending
- 2019-10-23 EP EP19875608.2A patent/EP3870223A4/en not_active Withdrawn
- 2019-10-23 KR KR1020217011641A patent/KR20210083260A/ko not_active Ceased
- 2019-10-23 CN CN201980067597.2A patent/CN112839677A/zh active Pending
- 2019-10-23 MX MX2021004660A patent/MX2021004660A/es unknown
- 2019-10-23 JP JP2021522078A patent/JP2022505663A/ja active Pending
- 2019-10-23 AU AU2019368289A patent/AU2019368289A1/en not_active Abandoned
- 2019-10-23 SG SG11202103720XA patent/SG11202103720XA/en unknown
-
2021
- 2021-03-30 IL IL281901A patent/IL281901A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505663A5 (enExample) | ||
| US11572388B2 (en) | Chimeric polypeptides and uses thereof | |
| KR20210083260A (ko) | 다가 IgM- 및 IgA-Fc 기반 결합 분자 | |
| AU2016206108B2 (en) | Monomeric Fc domains | |
| JP2022504822A5 (enExample) | ||
| JP2021514618A5 (enExample) | ||
| WO2020142625A4 (en) | Compositions for increasing half-life of a therapeutic agent in canines and methods of use | |
| CN118852460A (zh) | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) | |
| JP2024504728A5 (enExample) | ||
| US12448465B2 (en) | Peptides | |
| US20200399344A1 (en) | Nk cell-directed chimeric proteins | |
| JP2022548112A5 (enExample) | ||
| JP2023538902A (ja) | 操作されたリガンドを使用する材料及び方法 | |
| CN115724984A (zh) | 自身免疫b细胞消除剂分子及其用途 | |
| US20260049118A1 (en) | Single-chain chimeric polypeptides and uses thereof | |
| WO2022262832A1 (zh) | 双特异性融合蛋白 | |
| RU2021131461A (ru) | Биспецифичный слитый белок и его применение | |
| WO2026043906A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| JP2025527694A5 (enExample) | ||
| WO2023089079A1 (en) | Novel fusion protein specific for ox40 and pd-l1 | |
| NZ805407A (en) | D-domain containing polypeptides and uses thereof |